Genesystem Co. Ltd.
Genesystem Co., Ltd., a biotech engineering company, specializes in molecular testing solutions to target on-site testing needs. The company offers PCR systems, multiplex biochips, and PCR reagents. It also provides human pathogen assays, including novel coronavirus (SARS-CoV-2) detection kits, SARS-CoV-2/Flu/RSV simultaneous detection kits, and mycobacterium tuberculosis detection kits; veterina… Read more
Genesystem Co. Ltd. (363250) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.103x
Based on the latest financial reports, Genesystem Co. Ltd. (363250) has a cash flow conversion efficiency ratio of -0.103x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-1.60 Billion) by net assets (₩15.51 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Genesystem Co. Ltd. - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Genesystem Co. Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Genesystem Co. Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genesystem Co. Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
University Bancorp Inc
OTCQB:UNIB
|
0.049x |
|
Duluth Holdings Inc
NASDAQ:DLTH
|
-0.042x |
|
Eslite Spectrum
TWO:2926
|
0.889x |
|
Alony Hetz Properties and Investments Ltd
TA:ALHE
|
0.023x |
|
Zero to Seven Inc
KQ:159580
|
0.002x |
|
Company K Partners Limited
KQ:307930
|
-0.012x |
|
Lycos Energy Inc.
F:G4P0
|
0.075x |
|
Safe Bulkers Inc
NYSE:SB
|
0.040x |
Annual Cash Flow Conversion Efficiency for Genesystem Co. Ltd. (2018–2024)
The table below shows the annual cash flow conversion efficiency of Genesystem Co. Ltd. from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩19.27 Billion | ₩-7.34 Billion | -0.381x | -33.80% |
| 2023-12-31 | ₩27.46 Billion | ₩-7.81 Billion | -0.285x | -55.67% |
| 2022-12-31 | ₩35.11 Billion | ₩-6.42 Billion | -0.183x | -917.40% |
| 2021-12-31 | ₩44.09 Billion | ₩985.71 Million | 0.022x | -92.55% |
| 2020-12-31 | ₩12.32 Billion | ₩3.70 Billion | 0.300x | +82.12% |
| 2019-12-31 | ₩-12.70 Billion | ₩-2.09 Billion | 0.165x | -13.23% |
| 2018-12-31 | ₩-8.85 Billion | ₩-1.68 Billion | 0.190x | -- |